Good morning and welcome to another working week. We hope the weekend respite, which went by rather quickly, was refreshing and invigorating, because the usual routine of meetings, deadlines, and whatnot has returned. But you knew this would happen, yes? As always, we are coping by quaffing cups of stimulation. Our flavor today is Cinnamon Dolce, for those keeping track. Meanwhile, here are some tidbits. Have a lovely day and do keep in touch …
Pfizer has decided to remain a single company and not split its established and new medical lines into separate companies. In explaining its decision, the drug maker says its supposed “valuation gap” between its market cap and the value of its individual units has closed over time. Pfizer execs have debated the issue for years, but as we noted this summer, there were signs a split would not take place.
The US Food and Drug Administration is increasingly using an embargo tactic in which journalists must agree not to ask any questions of unapproved sources until given a go-ahead in exchange for an advance briefing about an upcoming announcement, Scientific American writes. By using a close-hold embargo, the FDA is gaining control of journalists who are supposed to keep an eye on those institutions.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect